

Appendix 1: Long-acting, injectable cabotegravir/rilpivirine for treatment of HIV-1 infection in adults(1,2)

Indications	Patients with HIV-1 infection who have had an undetectable (<50 copies/mL) viral load, on antiretroviral therapy Required duration of prior virologic suppression not defined, but was 1-6 months in registrational trials
Contraindications	Hepatitis B co-infection [requires a regimen containing tenofovir] Known resistance to either cabotegravir or rilpivirine Pregnancy or planning pregnancy [not studied in this population]
Drug Interactions	<p>Contraindicated:</p> <ul style="list-style-type: none"> - anticonvulsants [e.g. carbamazepine, oxcarbazepine, phenytoin, phenobarbital] - anti-mycobacterials [e.g. rifampin, rifapentine, rifabutin] - glucocorticoids [e.g. dexamethasone] - macrolides (except for azithromycin) - St. John's Wort <p>Caution when co-administered with:</p> <ul style="list-style-type: none"> - methadone - methotrexate - QT prolonging medications
Dosing and Administration	<p>Oral lead-in (optional): 30mg cabotegravir + 25mg rilpivirine once daily x 1 month, followed by:</p> <p>Intra-gluteal, intra-muscular (IM) injections: 600mg cabotegravir IM + 900mg rilpivirine IM x 1, followed by:</p> <ul style="list-style-type: none"> - 400mg cabotegravir IM + 600mg rilpivirine IM every 1 month OR - 600mg cabotegravir IM + 900mg rilpivirine IM at 1 month, and then 600mg cabotegravir IM + 900mg rilpivirine IM every 2 months <p>Patients may receive cabotegravir/rilpivirine up to 7 days before- or after- the scheduled date</p>
Known Risk Factors for Virologic Failure despite on-time injections	<p>BMI >30 kg/m²</p> <p>HIV subtype A6/A1</p> <p>Pro-viral rilpivirine resistance-associated mutations</p>

Adverse Events	<p>Injection site reactions (ISRs)</p> <ul style="list-style-type: none"> - median duration of ISRs is 3 days. - mostly mild and reduce in frequency over time <p>Less common adverse events (<2%):</p> <ul style="list-style-type: none"> - injection-associated reactions (pyrexia, headache, musculoskeletal pain, nausea, dizziness, rash) - gastrointestinal disorders - hepatotoxicity - psychiatric disorders - hypersensitivity
----------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

References

1. ViiV Healthcare ULC. Product Monograph Including Patient Medication Information - Vocabria and Cabenuva [Internet]. 2021 [cited 2023 Sep 13]. Available from: https://viiivhealthcare.com/content/dam/cf-viiv/viiv-healthcare/en_GB/medicines/CABENUVA-VOCABRIA-PM-26-Mar-2021.pdf
2. Cutrell AG, Schapiro JM, Perno CF, Kuritzkes DR, Quercia R, Patel P, et al. Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis. *AIDS*. 2021 Jul 15;35(9):1333–42.